問題一覧
1
1. Which of the following descriptions accurately reflects how the body uses cholesterol?
b. Formation of steroid hormones
2
The formation of atheromas in blood vessels precedes the signs and symptoms of
b. atherosclerotic cardiovascular disease.
3
3. Hyperlipidemia is considered to be a
c. treatable ASCVD risk factor
4
4. The bile acid sequestrants
d. prevent bile salts from being reabsorbed.
5
5. HMG-CoA reductase inhibitors work in the
b. process of cholesterol formation in the cell.
6
6. When teaching a patient about HMG-CoA reductase inhibitors, the nurse would include that the patient
c. might develop cataracts as a result.
7
7. Which would the nurse expect the health care provider to prescribe for a patient who has high lipid levels and cannot take fibrates or HMG-CoA reductase inhibitors?
c. PCSK9 inhibitor
8
5. Which would alert the nurse to suspect that a patient receiving HMG-CoA reductase inhibitors is developing rhabdomyelysis? a. Flatulence and abdominal bloating b. Increased bleeding and bruising Development of cataracts and blurred vision Muscle pain and weaknesss. Which would alert the nurse to suspect that a patient receiving HMG-CoA reductase inhibitors is developing rhabdomyelysis?
d. Muscle pain and weakness
9
general term used for drugs e used to lower lipid levels in the blood
antihyperlipidemic agents
10
formation of steroid hormones
cholesterol
11
cholesterol-containing acids found in the bile that act like detergents to break up fats in the small intestine
bile acids
12
carrier for lipids in the bloodstream, consisting of proteins, lipids, cholesterol, and other components
chylomicron
13
loosely packed chylomicron-containing fats, able to absorb fats and fat remnants in the periphery; thought to have a protective effect, decreasing the development of atherosclerotic cardiovascular disease
high-density lipoprotein (HDL)
14
enzyme that regulates the last step in cellular cholesterol synthesis
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase
15
increased levels of lipids in the serum, associated with increased risk of development of atherosclerotic cardiovascular disease
hyperlipidemia
16
tightly packed fats that are thought to contribute to the development of atherosclerotic cardiovascular disease when remnants left over trom the LDL are processed in the arterial lining
low-density lipoprotein
17
type of fat with a phosphate grous important structure to make lipoproteins, blood-clotting components, the myelin sheath, and cell membranes
phospholipids
18
collection of factors, including insulin resistance, abdominal obesity, low high-density lipoprotein, high triglyceride levels, hypertension, and proinflammatory and prothrombotic states, that increase the incidence.of atherosclerotic cardiovascular disease
metabolic syndrome
19
type of fat with a phosphate grous important structure to make lipoproteins, blood-clotting components, the myelin sheath, and cell membranes
proprotein convertase subtilisin/kexin type 9 (PCSK9)
20
type of lipid that is also called " neutral fat*: composed of fatty acids and a glycerol molecule; primarily used in the bedy as a source of energy
triglycerides
21
Reduction of risk of Mi, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, adjunet to diet, alone or in compination with other therapies to lower LDL, in adults with primary hyperlipidemia, adjunct to other therapies to lower LDL in adult patients with. homozygous familial hypercholesterolemia (HoFH) to reduce LDL
alirocumab (Praluent)
22
Reduction of risk of Ml. stroke, and coronary revascularzation in adults with cardiovascular disease, adjunct to diet, alone or in combination with other therapies to lower LDL, in adults with primary hyperlipidemia, adjunct to other therapies to lower LDL in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL
evolocumab (Repatha)